Mycenax Signs an Agreement with Gedeon Richter for LusiNEX

 Mycenax Signs an Agreement with Gedeon Richter for LusiNEX


  • Mycenax to sell LusiNEX project, including cell banks, CMC technology, intellectual properties, and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments as it completes the stages of asset transfer which will be utilized to operation and facility expansion which further strengthen Mycenax’s capacities in CDMO business
  • The focus of the agreement is to fully focus on its CDMO business and become one of the CDMO companies in Asia
  • LusiNEX is a biosimilar product of Actemra/ RoActemra and has completed its P-I demonstrating bioequivalence in 2018 and is expected to enter in P-III trial while further receiving market approval

Click here to read full press release/ article | Ref: Mycenax | Image: Pharmaworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post